≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Cleft hard palate NOS

Endpoint Browser PheWeb

Q17_CLEFT_HARD_PALATE_NOS

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

  • not Q17_CLEFT_PALATE_EXCLUDE
519067

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — Q35.1
  • Hospital discharge: ICD-9 — 7490X
  • Cause of death: ICD-10 — Q35.1
  • Cause of death: ICD-9 — 749

2 out of 7 registries used, show all original rules.

183

4. Check minimum number of events

None

183

5. Include endpoints

None

183

6. Filter based on genotype QC (FinnGen only)

176

Control definitions (FinnGen only)

Control conditions
not Q17_CLEFT_PALATE_EXCLUDE

Extra metadata

First used in FinnGen datafreeze
DF7

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 2587 1496 1087
Only index persons 2115 1232 883
Unadjusted period prevalence (%)
Whole population 0.04 0.04 0.03
Only index persons 0.04 0.05 0.03
Median age at first event (years)
Whole population 4.64 4.10 5.17
Only index persons 6.77 6.27 7.47

-FinnGen-

Key figures

All Female Male
Number of individuals 176 126 50
Unadjusted period prevalence (%) 0.04 0.04 0.02
Median age at first event (years) 15.01 16.02 12.46

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
183
Matched controls
1830
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
Q35.1
ICD-10 Finland
Cleft hard palate
+∞
255.8
180
*
4122
FHL
Tympanostomy (tympanic tube)
23.8
72.6
58
35
7490A
ICD-9 Finland
Cleft palate and cleft lip, Cleft palate[PALATOSCHISIS COMPLETA]
+∞
64.5
58
*
SBB00
NOMESCO Finland
Clinical photography of mouth and teeth
16.2
55.8
54
46
SJX10
NOMESCO Finland
Orthodontic treatment/control appointment, short
13.5
55.2
62
67
EB1MA
NOMESCO Finland
Cephalometry with X-ray
17.2
50.4
46
35
3812A
ICD-9 Finland
Nonsuppurative otitis media and Eustachian tube disorders, Chronic mucoid otitis media
19.1
50.2
43
29
4362
FHL
Nozzle reconstruction
621.5
49.9
47
*
SAA04
NOMESCO Finland
Special examination of mouth
12.8
47.9
54
58
74900
ICD-8 Finland
Cleft palate and cleft lip, Cleft palate
569.0
46.4
44
*
SBB10
NOMESCO Finland
Dental impressions
8.4
41.7
72
131
DCA20
NOMESCO Finland
Insertion of ventilating tube through tympanic membrane
10.7
36.4
45
54
4364
FHL
Pharyngeal tongue plastic
+∞
33.4
31
*
WZC10
NOMESCO Finland
Written specialist consultation based on a referral from a dentist or a physician
12.4
30.7
33
32
H65.3
ICD-10 Finland
Chronic mucoid otitis media
10.5
30.4
37
43
Q35.9
ICD-10 Finland
Cleft palate, unspecified
+∞
30.0
28
*
Q37.1
ICD-10 Finland
Cleft hard palate with unilateral cleft lip
178.2
29.6
30
*
SJC50
NOMESCO Finland
Removal of fixed orthodontic appliance with at least 7 brackets
10.2
27.6
34
40
SJD00
NOMESCO Finland
Removal and/or reactivation of orthodontic arch wire
9.0
27.4
38
52
7490B
ICD-9 Finland
Cleft palate and cleft lip, Cleft palate[PALATOSCHISIS INCOMPLETA]
301.1
26.4
26
*
SJB00
NOMESCO Finland
Fitting of removable appliance incl. patient instructions
8.7
24.2
34
47
Q35.3
ICD-10 Finland
Cleft soft palate
+∞
23.4
22
*
Q35.71
ICD-10 Finland
Submucous cleft palate
+∞
21.3
20
*
SJD20
NOMESCO Finland
Placement of modified orthodontic arch wire
8.6
18.3
25
33
EHC40
NOMESCO Finland
Repair of submucous cleft palate
+∞
18.0
17
*
Z2221
NOMESCO Finland
Medical doctor
3.8
17.4
82
322
K00.00
ICD-10 Finland
Hypodontia
20.0
15.6
23
13
4451
FHL
Guitar cutting
5.5
15.4
33
70
QA4S1
NOMESCO Finland
Photography of skin or subcutaneous tissue in face
62.0
15.1
17
*
K07.25
ICD-10 Finland
Anomalies of dental arch relationship
7.4
14.9
23
35
EEC05
NOMESCO Finland
Le Fort I osteotomy
87.3
14.8
16
*
Q37.0
ICD-10 Finland
Cleft hard palate with bilateral cleft lip
+∞
14.8
14
*
4368
FHL
Closing the fistula of the mouth
+∞
14.8
14
*
EHC10
NOMESCO Finland
Plastic repair of oronasal or oroantral fistula of palate
+∞
14.8
14
*
EBB10
NOMESCO Finland
Insertion of dental implant
39.6
14.7
18
5
ZXD10
NOMESCO Finland
Scheduled procedure
3.3
14.2
86
386
SJD30
NOMESCO Finland
Demanding placement of orthodontic arch wire
14.4
13.8
23
18
1450
FHL
Otomicroscopy
34.8
12.8
16
5
SAA03
NOMESCO Finland
Extended examination of mouth
3.2
12.7
119
675
EAB30
NOMESCO Finland
Correction of cleft lip
+∞
12.6
12
*
4361
FHL
Lip plastic or reconstruction due to cleft lip
139.1
12.6
13
*
H72.0
ICD-10 Finland
Central perforation of tympanic membrane
13.8
12.5
21
17
K08.1
ICD-10 Finland
Loss of teeth due to accident, extraction or local periodontal disease
5.0
12.4
29
66
UDC00
NOMESCO Finland
Ear microscopy
5.0
11.9
28
64
ENC80
NOMESCO Finland
Plastic operation of soft palate for voice distubance
+∞
11.6
11
*
SJD40
NOMESCO Finland
Placement of prefabricated palatal or lingual arch
5.5
11.6
24
49
ZXA10
NOMESCO Finland
Bilateral
3.6
11.6
47
162
SJD10
NOMESCO Finland
Placement of orthodontic arch wire
5.6
11.3
23
46
74920
ICD-8 Finland
Cleft palate and cleft lip, Cheilognathopalatoschisis unilateralis
63.8
10.8
12
*
SJA01
NOMESCO Finland
Assesment of orthodontic treatment need
63.8
10.8
12
*
SPA00
NOMESCO Finland
Changing form of teeth in prepation for prosthodontic work
13.2
10.6
18
15
ZXD30
NOMESCO Finland
Difficulties in perfomrming procedure
5.7
10.6
21
41
ZXB10
NOMESCO Finland
Medial
34.8
10.5
13
*
ZZH21
NOMESCO Finland
Graft of patients own bone, small pieces
25.1
10.4
14
6
EBB15
NOMESCO Finland
Insertion of dental implant abutment
58.2
9.8
11
*
7492A
ICD-9 Finland
Cleft palate and cleft lip, Cleft palate with cleft lip[CHEILOPALATOSCHISIS UNILATERALIS COMPLETA]
58.2
9.8
11
*
J01DA06
ATC
[U] cefuroxime
3.4
9.6
40
139
EHC30
NOMESCO Finland
Reconstruction of palate
+∞
9.5
9
*
ECB17
NOMESCO Finland
Operation of gingival cleft
+∞
9.5
9
*
Z01.1
ICD-10 Finland
Examination of ears and hearing
3.4
9.3
38
130
SJB60
NOMESCO Finland
Adjustment and grinding of removable appliance
8.2
9.2
20
27
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
2.6
8.9
109
666
ECB40
NOMESCO Finland
Surgical treatment of fracture of alveolus
52.6
8.8
10
*
K07.14
ICD-10 Finland
Retrognaty, maxillary
29.1
8.6
11
*
SJA04
NOMESCO Finland
Very demanding workplan for orthodontic treatment
94.2
8.5
9
*
EBB11
NOMESCO Finland
Insertion of additional dental implant in one session
+∞
8.4
8
*
H65.9
ICD-10 Finland
Nonsuppurative otitis media, unspecified
18.2
8.2
12
7
SPF10
NOMESCO Finland
Demanding reparation of dental prosthesis
35.1
8.2
10
*
SJC01
NOMESCO Finland
Positioning and fixed attachment of single bracket (Bracket with fixed attachment)
5.0
8.1
18
39
J01DA08
ATC
[U] cefaclor
2.7
7.7
52
236
SJA03
NOMESCO Finland
Demanding workplan for orthodontic treatment
26.3
7.7
10
*
ZXE10
NOMESCO Finland
More than one and less than three hours
2.5
7.6
66
338
DFF00
NOMESCO Finland
Pure tone audiometry
4.2
7.5
21
55
4365
FHL
Correction of nasal deformity
+∞
7.3
7
*
Q36.9
ICD-10 Finland
Cleft lip, unilateral
+∞
7.3
7
*
ZSZ10
NOMESCO Finland
Secondary repair operation
+∞
7.3
7
*
K07.30
ICD-10 Finland
Spacing, abnormal of tooth or teeth
4.0
7.1
21
57
H66.0
ICD-10 Finland
Acute suppurative otitis media
2.7
7.1
43
184
SJX11
NOMESCO Finland
Therapeutic intervention or check-up related to orthodontic treatment, restricted
4.0
6.8
20
54
EB1WA, ,
NOMESCO Finland
23.5
6.7
9
*
EBA10
NOMESCO Finland
Operative extraction of tooth
2.4
6.5
60
312
4141
FHL
Myringoplasty (also for reasons other than inflammation)
72.3
6.5
7
*
SPC30
NOMESCO Finland
Surface-retained bridge
72.3
6.5
7
*
SPC20
NOMESCO Finland
Implant borne crown
72.3
6.5
7
*
3842A
ICD-9 Finland
Other disorders of tympanic membrane, Perforation of tympanic membrane
72.3
6.5
7
*
EB1BI
NOMESCO Finland
Cone beam imaging of teeth and jaws (1–2 quarters)
11.6
6.4
11
10
EH1JB
NOMESCO Finland
Functional examination of palate
+∞
6.3
6
*
7490C
ICD-9 Finland
Cleft palate and cleft lip, Cleft palate[PALATOSCHISIS SUBMUCOSAE]
+∞
6.3
6
*
Q35
ICD-10 Finland
Cleft palate
+∞
6.3
6
*
7492C
ICD-9 Finland
Cleft palate and cleft lip, Cleft palate with cleft lip[CHEILOPALATOSCHISIS BILATERALIS COMPLETA]
+∞
6.3
6
*
SXC05
NOMESCO Finland
Other oral or dental procedure
2.9
6.2
31
119
SJX21
NOMESCO Finland
Therapeutic intervention or check-up related to orthodontic treatment
5.4
6.0
17
34
4121
FHL
Tympanic puncture or parasentosis in general anesthesia or operating room
7.7
6.0
13
18

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Dentistry
C5 [903277]
2.0e+00
2.8e+00
—
1.0e+50
1.0e+50
3.3e+00
2.5e+00
cases:11.27%
controls:1.63%
cases:11.97%
controls:0.78%
—
—
cases:23.24%
controls:0.00%
cases:10.56%
controls:0.00%
cases:23.40%
controls:1.14%
cases:27.66%
controls:3.02%
16
23
126
1385
17
11
125
1397
—
33
0
109
1408
15
0
127
1408
33
16
108
1391
39
42
102
1348
Plastic And Reconstructive Surgery
24 [38004467]
3.0e+00
3.7e+00
—
1.0e+50
—
—
3.9e+00
cases:16.20%
controls:0.92%
cases:14.79%
controls:0.43%
—
—
cases:23.94%
controls:0.00%
—
—
—
—
cases:36.88%
controls:1.15%
23
13
119
1395
21
6
121
1402
—
34
0
108
1408
—
—
52
16
89
1374
Otolaryngology
4 [38004449]
1.4e+00
1.7e+00
—
—
2.3e+00
1.5e+00
1.4e+00
cases:23.94%
controls:7.24%
cases:15.49%
controls:3.34%
—
—
—
—
cases:4.23%
controls:0.43%
cases:16.31%
controls:4.34%
cases:29.08%
controls:9.28%
34
102
108
1306
22
47
120
1361
—
—
6
6
136
1402
23
61
118
1346
41
129
100
1261
Medical doctor
Z2221 [2001311556]
1.5e+00
2.6e+00
—
1.0e+50
—
2.3e+00
1.7e+00
cases:6.34%
controls:1.49%
cases:6.34%
controls:0.50%
—
—
cases:7.04%
controls:0.00%
—
—
cases:6.38%
controls:0.71%
cases:7.80%
controls:1.51%
9
21
133
1387
9
7
133
1401
—
10
0
132
1408
—
9
10
132
1397
11
21
130
1369
Audiology
64 [38004489]
2.0e+00
2.3e+00
—
1.0e+50
1.0e+50
2.8e+00
2.5e+00
cases:4.93%
controls:0.71%
cases:3.52%
controls:0.36%
—
—
cases:4.23%
controls:0.00%
cases:3.52%
controls:0.00%
cases:5.67%
controls:0.36%
cases:9.93%
controls:0.86%
7
10
135
1398
5
5
137
1403
—
6
0
136
1408
5
0
137
1408
8
5
133
1402
14
12
127
1378
Outpatient Visit
OP [9202]
7.7e-01
7.6e-01
5.0e-01
—
1.5e+00
1.4e+00
1.4e+00
cases:58.45%
controls:39.49%
cases:53.52%
controls:35.09%
cases:15.49%
controls:10.01%
—
—
cases:31.69%
controls:9.45%
cases:71.63%
controls:37.88%
cases:85.82%
controls:60.14%
83
556
59
852
76
494
66
914
22
141
120
1267
—
45
133
97
1275
101
533
40
874
121
836
20
554
Chronic apical periodontitis
K04.5 [45586691]
2.5e+00
—
—
—
—
2.8e+00
—
cases:5.63%
controls:0.50%
—
—
—
—
—
—
—
—
cases:5.67%
controls:0.36%
—
—
8
7
134
1401
—
—
—
—
8
5
133
1402
—
Orthodontic treatment/control appointment, short
SJX10 [2001310452]
—
—
—
—
—
—
4.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:18.44%
controls:0.36%
—
—
—
—
—
—
26
5
115
1385
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
7.2e-01
5.0e-01
1.6e+00
—
1.6e+00
9.8e-01
6.4e-01
cases:27.46%
controls:15.63%
cases:12.68%
controls:8.10%
cases:4.23%
controls:0.85%
—
—
cases:5.63%
controls:1.14%
cases:19.15%
controls:8.17%
cases:34.75%
controls:21.94%
39
220
103
1188
18
114
124
1294
6
12
136
1396
—
8
16
134
1392
27
115
114
1292
49
305
92
1085
ibuprofen
R02AX02 [1588667]
7.2e-01
5.0e-01
1.6e+00
—
1.6e+00
9.8e-01
6.4e-01
cases:27.46%
controls:15.63%
cases:12.68%
controls:8.10%
cases:4.23%
controls:0.85%
—
—
cases:5.63%
controls:1.14%
cases:19.15%
controls:8.17%
cases:34.75%
controls:21.94%
39
220
103
1188
18
114
124
1294
6
12
136
1396
—
8
16
134
1392
27
115
114
1292
49
305
92
1085
General Surgery
2 [38004447]
6.6e-01
1.0e+00
—
—
—
1.7e+00
1.0e+00
cases:19.72%
controls:11.29%
cases:10.56%
controls:4.05%
—
—
—
—
—
—
cases:22.70%
controls:5.26%
cases:31.21%
controls:13.74%
28
159
114
1249
15
57
127
1351
—
—
—
32
74
109
1333
44
191
97
1199
More than one and less than three hours
ZXE10 [2001311401]
7.0e-01
—
—
—
—
2.0e+00
1.5e+00
cases:3.52%
controls:1.78%
—
—
—
—
—
—
—
—
cases:5.67%
controls:0.78%
cases:9.22%
controls:2.30%
5
25
137
1383
—
—
—
—
8
11
133
1396
13
32
128
1358
Scheduled procedure
ZXD10 [2001311387]
9.4e-01
1.3e+00
—
—
—
1.8e+00
1.6e+00
cases:5.63%
controls:2.27%
cases:4.23%
controls:1.21%
—
—
—
—
—
—
cases:7.09%
controls:1.28%
cases:13.48%
controls:3.09%
8
32
134
1376
6
17
136
1391
—
—
—
10
18
131
1389
19
43
122
1347
Extended examination of mouth
SAA03 [2001310276]
1.1e+00
2.0e+00
—
1.0e+50
—
9.4e-01
1.3e+00
cases:6.34%
controls:2.27%
cases:4.23%
controls:0.57%
—
—
cases:6.34%
controls:0.00%
—
—
cases:3.55%
controls:1.42%
cases:14.18%
controls:4.32%
9
32
133
1376
6
8
136
1400
—
9
0
133
1408
—
5
20
136
1387
20
60
121
1330
Anomalies of dental arch relationship
K07.25 [2000502771]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.96%
controls:0.36%
—
—
—
—
—
—
7
5
134
1385
Outpatient Hospital
22 [8756]
6.8e-01
6.4e-01
—
1.0e+50
—
1.3e+00
7.0e-01
cases:30.28%
controls:17.97%
cases:11.27%
controls:6.25%
—
—
cases:5.63%
controls:0.00%
—
—
cases:20.57%
controls:6.68%
cases:28.37%
controls:16.47%
43
253
99
1155
16
88
126
1320
—
8
0
134
1408
—
29
94
112
1313
40
229
101
1161
Nonsuppurative otitis media and Eustachian tube disorders, Chronic mucoid otitis media
3812A [2000403465]
2.5e+00
—
—
—
—
—
—
cases:4.23%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
6
5
136
1403
—
—
—
—
—
—
Written specialist consultation based on a referral from a dentist or a physician
WZC10 [2001310887]
—
—
—
1.0e+50
—
—
2.5e+00
—
—
—
—
—
—
cases:4.23%
controls:0.00%
—
—
—
—
cases:4.26%
controls:0.36%
—
—
—
6
0
136
1408
—
—
6
5
135
1385
Tympanostomy (tympanic tube)
4122 [2000100490]
2.5e+00
—
—
—
—
—
—
cases:4.93%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
7
6
135
1402
—
—
—
—
—
—
Operative extraction of tooth
EBA10 [2001301925]
2.3e+00
—
—
—
—
—
—
cases:4.93%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
7
7
135
1401
—
—
—
—
—
—
Oral Surgery
19 [38004464]
—
—
—
1.0e+50
—
—
2.3e+00
—
—
—
—
—
—
cases:4.23%
controls:0.00%
—
—
—
—
cases:4.96%
controls:0.50%
—
—
—
6
0
136
1408
—
—
7
7
134
1383
Extraction of tooth
EBA00 [2001301923]
2.1e+00
—
—
—
—
—
1.1e+00
cases:6.34%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
cases:8.51%
controls:3.02%
9
12
133
1396
—
—
—
—
—
12
42
129
1348
General Practice Dentistry
1223G0001X [38003675]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.38%
controls:0.94%
—
—
—
—
—
—
9
13
132
1377
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
7.0e-01
—
—
1.0e+50
—
1.8e+00
1.2e+00
cases:3.52%
controls:1.78%
—
—
—
—
cases:4.93%
controls:0.00%
—
—
cases:4.96%
controls:0.85%
cases:8.51%
controls:2.66%
5
25
137
1383
—
—
7
0
135
1408
—
7
12
134
1395
12
37
129
1353
Supplier / Service Provider
OMOP5117446 [33004]
-1.4e+00
—
-1.0e+50
—
—
—
3.0e+00
cases:4.23%
controls:15.41%
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
cases:7.09%
controls:0.36%
6
217
136
1191
—
0
11
142
1397
—
—
—
10
5
131
1385
doxycycline; oral, parenteral
J01AA02 [21602800]
1.4e-01
6.3e-01
—
—
—
1.2e+00
2.5e-01
cases:14.08%
controls:12.43%
cases:7.75%
controls:4.26%
—
—
—
—
—
—
cases:9.22%
controls:3.06%
cases:15.60%
controls:12.59%
20
175
122
1233
11
60
131
1348
—
—
—
13
43
128
1364
22
175
119
1215
acrivastine; oral
R06AX18 [21603518]
2.0e-01
—
—
—
—
—
1.0e+00
cases:6.34%
controls:5.26%
—
—
—
—
—
—
—
—
—
—
cases:12.06%
controls:4.75%
9
74
133
1334
—
—
—
—
—
17
66
124
1324
cough suppressants and expectorants
R05FB02 [21603442]
9.9e-01
—
—
—
—
—
4.8e-01
cases:12.68%
controls:5.11%
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:2.23%
18
72
124
1336
—
—
—
—
—
5
31
136
1359
dextromethorphan, combinations; oral
N07XX59 [43534835]
9.9e-01
—
—
—
—
—
4.8e-01
cases:12.68%
controls:5.11%
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:2.23%
18
72
124
1336
—
—
—
—
—
5
31
136
1359
promethazine, combinations
R06AD52 [21603489]
9.9e-01
—
—
—
—
—
4.8e-01
cases:12.68%
controls:5.11%
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:2.23%
18
72
124
1336
—
—
—
—
—
5
31
136
1359
dextromethorphan; oral
R05DA09 [21603404]
9.9e-01
—
—
—
—
—
4.8e-01
cases:12.68%
controls:5.11%
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:2.23%
18
72
124
1336
—
—
—
—
—
5
31
136
1359
hydroxyethylpromethazine, combinations
R06AD55 [21603490]
9.9e-01
—
—
—
—
—
4.8e-01
cases:12.68%
controls:5.11%
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:2.23%
18
72
124
1336
—
—
—
—
—
5
31
136
1359
fluticasone; nasal
R01AD08 [21605050]
-2.0e-01
5.5e-01
—
—
-1.0e+50
5.0e-01
9.8e-01
cases:5.63%
controls:6.82%
cases:4.93%
controls:2.91%
—
—
—
—
cases:0.00%
controls:0.57%
cases:4.96%
controls:3.06%
cases:14.18%
controls:5.83%
8
96
134
1312
7
41
135
1367
—
—
0
8
142
1400
7
43
134
1364
20
81
121
1309
fluticasone furoate; nasal
R01AD12 [21605053]
-2.0e-01
5.5e-01
—
—
-1.0e+50
5.0e-01
9.8e-01
cases:5.63%
controls:6.82%
cases:4.93%
controls:2.91%
—
—
—
—
cases:0.00%
controls:0.57%
cases:4.96%
controls:3.06%
cases:14.18%
controls:5.83%
8
96
134
1312
7
41
135
1367
—
—
0
8
142
1400
7
43
134
1364
20
81
121
1309
phenylpropanolamine, combinations; oral
R01BA51 [21603212]
9.6e-01
—
—
—
—
—
3.8e-01
cases:12.68%
controls:5.26%
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:2.45%
18
74
124
1334
—
—
—
—
—
5
34
136
1356
chlorphenamine, combinations
R06AB54 [21603468]
9.6e-01
—
—
—
—
—
5.4e-01
cases:12.68%
controls:5.26%
—
—
—
—
—
—
—
—
—
—
cases:4.26%
controls:2.52%
18
74
124
1334
—
—
—
—
—
6
35
135
1355
phenylephrine, combinations
R01BA53 [21603214]
9.6e-01
—
—
—
—
—
5.4e-01
cases:12.68%
controls:5.26%
—
—
—
—
—
—
—
—
—
—
cases:4.26%
controls:2.52%
18
74
124
1334
—
—
—
—
—
6
35
135
1355
opium derivatives and expectorants
R05FA02 [21603439]
9.6e-01
—
—
—
—
—
3.8e-01
cases:12.68%
controls:5.26%
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:2.45%
18
74
124
1334
—
—
—
—
—
5
34
136
1356
cefalexin; oral
J01DB01 [21602870]
4.8e-01
2.8e-01
—
—
1.6e+00
6.2e-01
8.6e-01
cases:33.10%
controls:23.44%
cases:8.45%
controls:6.53%
—
—
—
—
cases:4.23%
controls:0.85%
cases:11.35%
controls:6.47%
cases:44.68%
controls:25.40%
47
330
95
1078
12
92
130
1316
—
—
6
12
136
1396
16
91
125
1316
63
353
78
1037
Allergy, unspecified
T78.4 [45580373]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
141
1385
Female infertility, unspecified
N97.9 [45582432]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
—
—
—
—
—
—
chlorprothixene; oral, parenteral
N05AF03 [21604533]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
142
1402
—
—
—
—
—
—
Open wound of other parts of wrist and hand
S61.8 [45588506]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
6
141
1384
Trichilemmal cyst
L72.1 [45596386]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
6
141
1384
Sensorineural hearing loss, unilateral with unrestricted hearing on the contralateral side
H90.4 [45572067]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
141
1385
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
—
—
-1.0e+50
—
—
—
1.1e-01
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
cases:8.51%
controls:7.70%
—
—
0
11
142
1397
—
—
—
12
107
129
1283
Other specified counselling
Z71.8 [45581061]
—
—
—
—
—
-1.0e+50
3.0e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
cases:3.55%
controls:2.66%
—
—
—
—
—
0
6
141
1401
5
37
136
1353
Cystoscopy
UKC02 [2001306005]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
—
—
—
—
—
Cholesterol [Moles/volume] in Serum or Plasma
14647-2 [3019900]
-2.5e-01
1.5e-01
-1.0e+50
—
—
1.3e-01
-2.3e-01
cases:3.52%
controls:4.47%
cases:3.52%
controls:3.05%
cases:0.00%
controls:0.99%
—
—
—
—
cases:3.55%
controls:3.13%
cases:7.09%
controls:8.78%
5
63
137
1345
5
43
137
1365
0
14
142
1394
—
—
5
44
136
1363
10
122
131
1268
Rotator cuff syndrome
M75.1 [45596678]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.44%
0
8
142
1400
—
—
—
—
—
0
20
141
1370
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
-1.7e-01
3.6e-01
—
—
—
1.3e-01
3.0e-01
cases:4.23%
controls:4.97%
cases:3.52%
controls:2.49%
—
—
—
—
—
—
cases:3.55%
controls:3.13%
cases:10.64%
controls:8.13%
6
70
136
1338
5
35
137
1373
—
—
—
5
44
136
1363
15
113
126
1277
Administration of medicine
SPAT1254 [2001700355]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
0
7
141
1383
Diabetes non-insulin dependent
T90 [2002001131]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.57%
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
0
8
142
1400
0
7
142
1401
—
—
—
—
—
oxybutynin; oral, transdermal
G04BD04 [21602637]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
—
—
—
—
—
—
hydrocortisone
S02BA01 [21605166]
2.7e-02
—
—
—
—
—
6.8e-01
cases:6.34%
controls:6.18%
—
—
—
—
—
—
—
—
—
—
cases:9.22%
controls:4.89%
9
87
133
1321
—
—
—
—
—
13
68
128
1322
No procedures
SPAT1301 [2001700402]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.28%
cases:0.00%
controls:0.50%
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
0
18
142
1390
0
7
142
1401
—
—
—
0
10
141
1397
—
Person consulting for explanation of investigation findings
Z71.2 [45552100]
1.7e+00
—
—
—
—
-1.0e+50
—
cases:3.52%
controls:0.64%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
5
9
137
1399
—
—
—
—
0
5
141
1402
—
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
—
-1.0e+50
—
—
—
-1.0e+50
2.7e-01
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
cases:0.00%
controls:0.78%
cases:3.55%
controls:2.73%
—
0
14
142
1394
—
—
—
0
11
141
1396
5
38
136
1352
Gastroenterology
10 [38004455]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
142
1394
—
—
—
—
—
—
salbutamol; oral, parenteral
R03CC02 [21603312]
7.8e-01
—
-1.0e+50
—
—
—
7.3e-01
cases:14.79%
controls:7.39%
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:4.96%
controls:2.45%
21
104
121
1304
—
0
5
142
1403
—
—
—
7
34
134
1356
chloramphenicol
D10AF03 [21602307]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
8
141
1382
Endocrinology
46 [38004485]
-1.0e+50
—
-1.0e+50
—
-1.0e+50
-1.0e+50
—
cases:0.00%
controls:1.28%
—
—
cases:0.00%
controls:0.43%
—
—
cases:0.00%
controls:0.36%
cases:0.00%
controls:1.42%
—
—
0
18
142
1390
—
0
6
142
1402
—
0
5
142
1403
0
20
141
1387
—
lercanidipine; oral
C08CA13 [21601759]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.57%
cases:0.00%
controls:0.57%
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
0
8
142
1400
0
8
142
1400
—
—
—
0
8
141
1399
—
Preventive oral health care
SCA02 [2001310303]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
14
141
1376
Spirometry study
18759-1 [3000492]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
141
1385
Acute bronchitis, unspecified
J20.9 [45562445]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
142
1399
—
—
—
—
—
—
Bacteria [Presence] in Urine
87829-8 [36304419]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
142
1398
—
—
—
—
—
—
Choriogonadotropin [Presence] in Serum or Plasma
2118-8 [3003191]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
141
1385
candesartan; oral
C09CA06 [21601829]
—
—
—
—
—
—
7.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:1.73%
—
—
—
—
—
—
5
24
136
1366
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.71%
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
0
10
142
1398
0
5
142
1403
—
—
—
0
7
141
1400
—
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
—
—
-1.0e+50
—
—
—
-7.8e-02
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
cases:7.09%
controls:7.63%
—
—
0
13
142
1395
—
—
—
10
106
131
1284
Laboratory test
15220000 [4034850]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
0
13
141
1377
Base excess in Venous blood by calculation
1927-3 [3002032]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
6
141
1384
Hallux valgus (acquired)
M20.1 [45606152]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
—
—
—
—
—
—
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: current
SMOKING-1-1-1 [2002330115]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
142
1395
—
—
—
—
—
—
naproxen; oral, rectal
M01AE02 [21603968]
4.7e-01
6.0e-01
—
—
—
9.0e-01
-2.4e-01
cases:14.79%
controls:9.80%
cases:4.93%
controls:2.77%
—
—
—
—
—
—
cases:6.38%
controls:2.70%
cases:6.38%
controls:7.99%
21
138
121
1270
7
39
135
1369
—
—
—
9
38
132
1369
9
111
132
1279
valdecoxib; oral
M01AH03 [21603994]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
0
9
141
1381
Contraception intrauterine
W12 [2002001212]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
0
8
142
1400
—
—
—
—
—
0
9
141
1381
Acute upper respiratory infection, unspecified
J06.9 [45562437]
—
—
—
—
—
—
1.2e-04
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.96%
controls:4.96%
—
—
—
—
—
—
7
69
134
1321
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
0
5
141
1402
—
metronidazole; oral, rectal
P01AB01 [21604857]
1.0e-01
-1.0e+50
—
—
—
—
3.5e-01
cases:3.52%
controls:3.20%
cases:0.00%
controls:1.14%
—
—
—
—
—
—
—
—
cases:4.26%
controls:3.02%
5
45
137
1363
0
16
142
1392
—
—
—
—
6
42
135
1348
insulin degludec; parenteral
A10AE06 [43534747]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
141
1385
Other obstetric ultrasound examination
MA2XE [2001306838]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
142
1402
—
—
—
—
—
—
Laparoscopic unilateral salpingo-oophorectomy
LAF01 [2001306442]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
141
1385
Cholesterol non HDL [Moles/volume] in Serum or Plasma
70204-3 [42868678]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
8
141
1382
moxifloxacin; oral, parenteral
J01MA14 [21603021]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
141
1385
mometasone
D07AC13 [21602132]
—
-1.0e+50
—
—
—
—
8.0e-01
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
cases:4.96%
controls:2.30%
—
0
10
142
1398
—
—
—
—
7
32
134
1358
General symptom/complaint other
A29 [2002000163]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
0
7
141
1383
Periodontal treatment by dental hygienist, extensive
SDE03 [2001310351]
—
—
—
—
—
-1.0e+50
6.2e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
cases:3.55%
controls:1.94%
—
—
—
—
—
0
5
141
1402
5
27
136
1363
Other hypothyroidism
E03 [45581337]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
0
7
141
1383
Early examination of pregnancy
XMA20 [2001306915]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
141
1385
erythromycin; oral, parenteral
J01FA01 [21602970]
1.2e-01
—
—
—
—
—
-1.0e+50
cases:6.34%
controls:5.68%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
9
80
133
1328
—
—
—
—
—
0
12
141
1378
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: occasional
SMOKING-1-1-2 [2002330117]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
142
1402
—
—
—
—
—
—
Thyroperoxidase Ab [Units/volume] in Serum or Plasma
8099-4 [3027238]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
8
141
1382
Skin texture symptom/complaint
S21 [2002000986]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
8
141
1382
pH of Venous blood
2746-6 [3012544]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
6
141
1384
Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
0
14
141
1393
—
Excessive bleeding in the premenopausal period
N92.4 [45606518]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
—
—
—
—
—
—
Pharmacy visit
OMOP4822462 [581458]
4.4e-01
-2.4e-02
-1.4e-01
8.9e-01
2.7e-01
1.3e-01
3.1e-01
cases:92.25%
controls:88.49%
cases:68.31%
controls:68.82%
cases:22.54%
controls:25.07%
cases:4.23%
controls:1.78%
cases:29.58%
controls:24.29%
cases:70.21%
controls:67.45%
cases:90.78%
controls:87.84%
131
1246
11
162
97
969
45
439
32
353
110
1055
6
25
136
1383
42
342
100
1066
99
949
42
458
128
1221
13
169
Other and unspecified abdominal pain
R10.4 [45568113]
4.8e-01
—
—
—
—
—
—
cases:3.52%
controls:2.20%
—
—
—
—
—
—
—
—
—
—
—
—
5
31
137
1377
—
—
—
—
—
—
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: Unspecified
SMOKING-2-2-0 [2002330110]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.28%
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
0
18
142
1390
0
10
142
1398
—
—
—
—
—
dydrogesterone; oral
G03DB01 [21602544]
1.2e+00
—
—
—
—
-1.0e+50
7.8e-01
cases:3.52%
controls:1.07%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
cases:3.55%
controls:1.65%
5
15
137
1393
—
—
—
—
0
7
141
1400
5
23
136
1367
Gynecological ultrasound examination as part of clinical examination
LX1AE [2001306815]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
142
1402
—
—
—
—
—
—
Genetic counselling
Z31.5 [45590715]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
142
1397
—
—
—
—
—
—
Demanding periodontal treatment
SDA04 [2001310329]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
0
7
142
1401
—
—
—
0
11
141
1396
—
Basic examination of mouth
SAA02 [2001310275]
5.7e-01
1.4e+00
—
—
—
1.1e+00
6.3e-01
cases:8.45%
controls:4.97%
cases:6.34%
controls:1.70%
—
—
—
—
—
—
cases:6.38%
controls:2.20%
cases:17.02%
controls:9.86%
12
70
130
1338
9
24
133
1384
—
—
—
9
31
132
1376
24
137
117
1253
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
0
7
141
1383
Lower uterine segment caesarean section
MCA10 [2001306959]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
—
—
—
—
—
Chronic disease of tonsils and adenoids, Hypertrophy of tonsils and adenoids[HYPERTROPHIA TONSILLAE PHARYNGICAE]
4741B [2000403921]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
142
1399
—
—
—
—
—
—
Other obesity
E66.8 [45533036]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
0
9
141
1381
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
-1.0e+50
—
—
—
—
-1.0e+50
9.7e-01
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
cases:4.26%
controls:1.65%
0
14
142
1394
—
—
—
—
0
7
141
1400
6
23
135
1367
tiaprofenic acid; oral, rectal
M01AE11 [21603977]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
—
—
—
—
—
—
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
-1.1e-01
—
-1.0e+50
—
—
—
1.3e-01
cases:4.23%
controls:4.69%
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
cases:9.93%
controls:8.85%
6
66
136
1342
—
0
9
142
1399
—
—
—
14
123
127
1267
pivmecillinam; oral
J01CA08 [21602827]
4.4e-01
—
—
—
—
8.9e-01
2.6e-01
cases:5.63%
controls:3.69%
—
—
—
—
—
—
—
—
cases:3.55%
controls:1.49%
cases:8.51%
controls:6.69%
8
52
134
1356
—
—
—
—
5
21
136
1386
12
93
129
1297
Cough
R05 [2002000886]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
—
—
—
—
—
—
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
0
10
142
1398
—
—
—
—
0
12
141
1378
fluoxetine; oral
N06AB03 [21604711]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
0
7
142
1401
—
—
—
0
8
141
1399
—
isosorbide dinitrate; local oral, oral, sublingual, transdermal
C01DA08 [21600321]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.57%
cases:0.00%
controls:0.64%
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
0
8
142
1400
0
9
142
1399
—
—
—
0
7
141
1400
—
Acute tonsillitis, unspecified
J03.9 [45576942]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
0
7
141
1400
—
Periodontal treatment, very brief
SDA01 [2001310326]
—
—
—
—
—
—
6.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.26%
controls:2.23%
—
—
—
—
—
—
6
31
135
1359
Verruca simplex
B07.9 [2000500357]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.36%
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
0
5
142
1403
—
—
—
—
—
piroxicam; oral, parenteral, rectal
M01AC01 [21603961]
2.1e-01
—
—
—
—
-1.0e+50
—
cases:4.93%
controls:4.05%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
7
57
135
1351
—
—
—
—
0
10
141
1397
—
hydrocortisone; oral, parenteral
H02AB09 [21602737]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
—
—
—
—
—
Depressive episode, unspecified
F32.9 [45571760]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
0
5
141
1402
—
Hypothyroidism, unspecified
E03.9 [45537945]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
0
5
141
1402
—
General medical examination
Z00.0 [45585791]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
11
141
1379
Initiation, adjustment, discontinuation or repetition of medication
SPAT1253 [2001700354]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
0
11
142
1397
—
—
—
—
0
8
141
1399
—
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
0
7
141
1383
Personal history of leukaemia
Z85.6 [45609980]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
6
141
1384
Cleft hard palate
Q35.1 [45539274]
—
—
—
1.0e+50
1.0e+50
1.0e+50
1.0e+50
—
—
—
—
—
—
cases:90.14%
controls:0.00%
cases:25.35%
controls:0.00%
cases:44.68%
controls:0.00%
cases:49.65%
controls:0.00%
—
—
—
128
0
14
1408
36
0
106
1408
63
0
78
1407
70
0
71
1390
terbinafine; oral
D01BA02 [21601967]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
—
—
—
—
—
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
-2.1e-02
-2.7e-01
—
—
—
-4.1e-02
6.9e-02
cases:6.34%
controls:6.46%
cases:4.23%
controls:5.47%
—
—
—
—
—
—
cases:5.67%
controls:5.90%
cases:12.77%
controls:12.01%
9
91
133
1317
6
77
136
1331
—
—
—
8
83
133
1324
18
167
123
1223
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.28%
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
0
18
142
1390
0
9
142
1399
—
—
—
—
—
Adenotomy
EMB30 [2001302268]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
141
1385
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
142
1400
—
—
—
—
—
—
sertraline; oral
N06AB06 [21604714]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
cases:0.00%
controls:0.86%
—
—
—
—
—
0
6
141
1401
0
12
141
1378
Lamotrigin and topiramate
183 [2001600182]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
—
—
—
—
—
—
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
—
—
-1.0e+50
—
-1.0e+50
—
6.3e-01
—
—
—
—
cases:0.00%
controls:0.43%
—
—
cases:0.00%
controls:0.43%
—
—
cases:7.80%
controls:4.32%
—
—
0
6
142
1402
—
0
6
142
1402
—
11
60
130
1330
cefadroxil; oral
J01DB05 [21602874]
4.3e-01
—
—
—
—
—
—
cases:7.75%
controls:5.18%
—
—
—
—
—
—
—
—
—
—
—
—
11
73
131
1335
—
—
—
—
—
—
Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 [3001308]
-4.3e-02
2.9e-01
-1.0e+50
—
—
4.0e-02
-1.8e-01
cases:4.23%
controls:4.40%
cases:4.23%
controls:3.20%
cases:0.00%
controls:1.07%
—
—
—
—
cases:3.55%
controls:3.41%
cases:7.80%
controls:9.21%
6
62
136
1346
6
45
136
1363
0
15
142
1393
—
—
5
48
136
1359
11
128
130
1262
IgE [Units/volume] in Serum or Plasma
19113-0 [3005322]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
142
1402
—
—
—
—
—
—
Breathing problem other
R04 [2002000885]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
141
1385
Ultrasound examination of early pregnancy (before 12. postmenstrual week)
MA1AE [2001306827]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.08%
—
—
—
—
—
—
0
15
141
1375
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
0
5
142
1403
—
—
—
0
5
141
1402
—
Allergic rhinitis due to pollen
J30.10 [2000502594]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
0
5
142
1403
—
—
—
—
—
0
9
141
1381
Insertion of dental implant
EBB10 [2001301936]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:0.00%
—
—
—
—
—
—
—
5
0
136
1407
—
Mental and behavioural disorders due to use of alcohol, Harmful use
F10.1 [45595844]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
8
141
1382
insulin detemir; parenteral
A10AE05 [21600740]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.92%
cases:0.00%
controls:0.78%
—
—
—
—
—
—
cases:0.00%
controls:0.78%
cases:0.00%
controls:1.44%
0
13
142
1395
0
11
142
1397
—
—
—
0
11
141
1396
0
20
141
1370
Treatment plan or consultation
WZC00 [2001310885]
1.4e+00
—
—
1.0e+50
—
—
1.2e+00
cases:4.93%
controls:1.28%
—
—
—
—
cases:4.23%
controls:0.00%
—
—
—
—
cases:7.09%
controls:2.30%
7
18
135
1390
—
—
6
0
136
1408
—
—
10
32
131
1358
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
142
1402
—
—
—
—
—
—
Psychiatry
26 [38004469]
7.7e-01
—
—
—
—
—
4.3e-01
cases:4.93%
controls:2.34%
—
—
—
—
—
—
—
—
—
—
cases:6.38%
controls:4.24%
7
33
135
1375
—
—
—
—
—
9
59
132
1331
Recurrent depression, moderate episode of somatic syndrome
F33.11 [2000501985]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
141
1385
combinations of corticosteroids
D07XB30 [21602188]
4.6e-01
—
-1.0e+50
—
—
—
1.1e-01
cases:9.86%
controls:6.46%
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
cases:7.09%
controls:6.40%
14
91
128
1317
—
0
7
142
1401
—
—
—
10
89
131
1301
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: former
SMOKING-2-2-4 [2002330109]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.85%
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
0
12
142
1396
0
7
142
1401
—
—
—
—
—
glucosamine; oral
M01AX05 [21604002]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.21%
cases:0.00%
controls:0.78%
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
0
17
142
1391
0
11
142
1397
—
—
—
0
11
141
1396
—
Neurology
13 [38004458]
5.2e-01
1.2e+00
—
—
—
9.8e-01
6.5e-01
cases:4.93%
controls:2.98%
cases:3.52%
controls:1.14%
—
—
—
—
—
—
cases:4.96%
controls:1.92%
cases:7.80%
controls:4.24%
7
42
135
1366
5
16
137
1392
—
—
—
7
27
134
1380
11
59
130
1331
Cardiology
6 [38004451]
—
—
—
—
—
—
9.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.96%
controls:2.01%
—
—
—
—
—
—
7
28
134
1362
Cystocele
N81.1 [45558171]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
8
141
1382
azelastine; nasal
R01AC03 [21605035]
—
—
—
—
—
—
9.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:1.37%
—
—
—
—
—
—
5
19
136
1371
mefenamic acid; oral
M01AG01 [21603987]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
142
1402
—
—
—
—
—
—
prednisolone
A07EA01 [21600653]
—
—
—
—
—
6.3e-01
8.4e-01
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:1.92%
cases:10.64%
controls:4.89%
—
—
—
—
—
5
27
136
1380
15
68
126
1322
Hypertrophy of adenoids
J35.2 [45552887]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
142
1399
—
—
—
—
—
—
long-acting sulfonamides - combinations
J01ED20 [21602959]
7.2e-01
—
—
—
—
—
5.5e-01
cases:6.34%
controls:3.20%
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:2.09%
9
45
133
1363
—
—
—
—
—
5
29
136
1361
Gonarthrosis [arthrosis of knee]
M17 [45601350]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
6
141
1384
Left side
ZXA05 [2001311347]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:1.08%
—
—
—
—
—
—
5
15
136
1375
covid-19, RNA-based vaccine
J07BN01 [954934]
-1.0e+50
—
—
—
—
—
2.6e-03
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
cases:4.26%
controls:4.24%
0
12
142
1396
—
—
—
—
—
6
59
135
1331
Maternal care due to uterine scar from previous surgery
O34.2 [45572805]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
—
—
—
—
—
—
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
—
6.7e-01
—
—
cases:0.00%
controls:0.85%
cases:0.00%
controls:0.50%
—
—
cases:0.00%
controls:0.43%
—
—
cases:4.26%
controls:2.23%
—
0
12
142
1396
0
7
142
1401
—
0
6
142
1402
—
6
31
135
1359
Treponema pallidum Ab [Presence] in Serum
22587-0 [3019832]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
cases:0.00%
controls:0.86%
0
5
142
1403
—
—
—
—
0
8
141
1399
0
12
141
1378
Oxygen [Partial pressure] in Venous blood
2705-2 [3024354]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
142
1402
—
—
—
—
—
—
acetylsalicylic acid, combinations excl. psycholeptics
N02BA51 [21604320]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
142
1401
—
—
—
—
—
—
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
-2.1e-02
-2.7e-01
—
—
—
-4.1e-02
6.9e-02
cases:6.34%
controls:6.46%
cases:4.23%
controls:5.47%
—
—
—
—
—
—
cases:5.67%
controls:5.90%
cases:12.77%
controls:12.01%
9
91
133
1317
6
77
136
1331
—
—
—
8
83
133
1324
18
167
123
1223
Pediatric Gastroenterology
OMOP4822029 [45756810]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
142
1402
—
—
—
—
—
—
Chronic disease of tonsils and adenoids, Chronic tonsillitis
4740A [2000403919]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
142
1402
—
—
—
—
—
—
One hour or less
ZXE00 [2001311394]
1.2e-01
—
—
—
—
1.3e+00
6.6e-01
cases:4.23%
controls:3.76%
—
—
—
—
—
—
—
—
cases:4.96%
controls:1.42%
cases:7.09%
controls:3.81%
6
53
136
1355
—
—
—
—
7
20
134
1387
10
53
131
1337
phenylpropanolamine; oral
R01BA01 [21603209]
1.2e+00
—
—
—
—
—
—
cases:4.93%
controls:1.49%
—
—
—
—
—
—
—
—
—
—
—
—
7
21
135
1387
—
—
—
—
—
—
Mucopurulent conjunctivitis
H10.0 [45596007]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
0
6
141
1401
—
Hyperplasia of prostate
N40 [45563015]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
0
7
141
1383
naproxcinod
M01AE18 [40254094]
4.7e-01
6.0e-01
—
—
—
9.0e-01
-2.4e-01
cases:14.79%
controls:9.80%
cases:4.93%
controls:2.77%
—
—
—
—
—
—
cases:6.38%
controls:2.70%
cases:6.38%
controls:7.99%
21
138
121
1270
7
39
135
1369
—
—
—
9
38
132
1369
9
111
132
1279
Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ and CD8+ T-cells [Units/volume] in Blood
88518-6 [36304997]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
—
—
—
—
—
—
insulin (human); parenteral
A10AD01 [21600729]
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
0
6
142
1402
—
—
—
Vomiting
D10 [2002000309]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
0
7
141
1383
hydrocortisone buteprate
D07AB11 [21602115]
1.6e-01
—
—
—
—
—
5.9e-01
cases:7.75%
controls:6.68%
—
—
—
—
—
—
—
—
—
—
cases:9.22%
controls:5.32%
11
94
131
1314
—
—
—
—
—
13
74
128
1316
ondansetron; oral, parenteral, rectal
A04AA01 [21600493]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
0
7
141
1383
Asthma, Extrinsic asthma[EXTRINSIC ASTHMA SINE EXACERBATIONE]
4930A [2000403991]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
142
1399
—
—
—
—
—
—
fusidic acid
D09AA02 [21602265]
2.7e-01
-1.0e+50
—
—
—
-1.0e+50
9.7e-01
cases:3.52%
controls:2.70%
cases:0.00%
controls:0.64%
—
—
—
—
—
—
cases:0.00%
controls:0.57%
cases:4.26%
controls:1.65%
5
38
137
1370
0
9
142
1399
—
—
—
0
8
141
1399
6
23
135
1367
empagliflozin; oral
A10BK03 [1123740]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.36%
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:0.00%
controls:0.36%
cases:0.00%
controls:0.36%
0
5
142
1403
0
5
142
1403
—
—
—
0
5
141
1402
0
5
141
1385
Consultation of another employee
SPAT1260 [2001700361]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
0
9
141
1381
Back symptom/complaint
L02 [2002000627]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
141
1385
Mixed asthma
J45.8 [45548118]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
0
7
141
1383
pantoprazole; oral, parenteral
A02BC02 [21600097]
8.7e-03
1.0e+00
—
—
-1.0e+50
—
5.4e-01
cases:4.23%
controls:4.19%
cases:4.23%
controls:1.56%
—
—
—
—
cases:0.00%
controls:0.50%
—
—
cases:9.22%
controls:5.61%
6
59
136
1349
6
22
136
1386
—
—
0
7
142
1401
—
13
78
128
1312
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
3.1e-01
1.0e-01
-1.0e+50
—
—
6.3e-01
2.5e-01
cases:4.23%
controls:3.13%
cases:3.52%
controls:3.20%
cases:0.00%
controls:0.99%
—
—
—
—
cases:4.96%
controls:2.70%
cases:8.51%
controls:6.76%
6
44
136
1364
5
45
137
1363
0
14
142
1394
—
—
7
38
134
1369
12
94
129
1296
General examination of pregnant woman
XMA22 [2001306916]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.08%
0
5
142
1403
—
—
—
—
—
0
15
141
1375
Glucose tolerance 2 hours panel - Serum or Plasma
72171-2 [43054914]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
0
7
142
1401
—
—
—
—
0
5
141
1402
—
betamethasone
D07AC01 [21602120]
7.9e-01
—
—
—
—
—
2.4e-01
cases:5.63%
controls:2.63%
—
—
—
—
—
—
—
—
—
—
cases:4.96%
controls:3.96%
8
37
134
1371
—
—
—
—
—
7
55
134
1335
Emergency procedure
ZXD00 [2001311385]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
142
1399
—
—
—
—
—
—
Gastro-oesophageal reflux disease with oesophagitis
K21.0 [45543296]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
0
7
141
1383
Supervision of normal pregnancy
Z34 [45566419]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
—
—
—
—
—
—
Weakness/tiredness general
A04 [2002000145]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
—
—
—
—
—
—
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.21%
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
0
17
142
1391
0
5
142
1403
—
—
—
0
10
141
1397
—
Extensive MRI examination of brain with high intensity magnet
AA1CG [2001300116]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
0
7
142
1401
—
—
—
—
—
0
5
141
1385
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
—
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
—
—
cases:0.00%
controls:1.49%
—
—
—
—
cases:0.00%
controls:0.57%
cases:0.00%
controls:1.21%
—
—
—
0
21
142
1387
—
—
0
8
142
1400
0
17
141
1390
—
Irrigation or wax removal of outer auditory canal
SPAT1033 [2001700134]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
0
5
142
1403
—
—
—
—
—
0
7
141
1383
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
142
1401
—
—
—
—
—
—
tolfenamic acid; oral, rectal
M01AG02 [21603988]
7.9e-01
—
—
—
—
—
—
cases:3.52%
controls:1.63%
—
—
—
—
—
—
—
—
—
—
—
—
5
23
137
1385
—
—
—
—
—
—
Antenatal screening
243787009 [4087235]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
0
7
141
1383
zafirlukast; oral
R03DC01 [21603354]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
6
141
1384
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
11
141
1379
Fall on same level involving ice and snow
W00 [45756242]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
—
—
—
—
—
Unilateral or unspecified inguinal hernia, without obstruction or gangrene
K40.9 [45543307]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
142
1400
—
—
—
—
—
—
Other blockage of nerve
WX290 [2001310792]
9.3e-01
—
—
—
—
—
—
cases:4.23%
controls:1.70%
—
—
—
—
—
—
—
—
—
—
—
—
6
24
136
1384
—
—
—
—
—
—
Drug-induced hypoglycaemia without coma
E16.0 [45571666]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
—
—
—
—
—
—
Cleft hard palate with unilateral cleft lip
Q37.1 [45582645]
—
1.0e+50
—
—
—
1.0e+50
—
—
—
cases:10.56%
controls:0.00%
—
—
—
—
—
—
cases:9.22%
controls:0.00%
—
—
—
15
0
127
1408
—
—
—
13
0
128
1407
—
Metamyelocytes/Leukocytes in Blood
28541-1 [3002179]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
141
1385
sulfamethoxazole and trimethoprim
J01EE01 [21602961]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
142
1401
—
—
—
—
—
—
Conjunctivitis
H10 [45581570]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
8
141
1382
Type 2 diabetes mellitus
E11 [45571656]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
142
1396
—
—
—
—
—
—
formoterol and budesonide
R03AK07 [21603281]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
—
—
—
—
—
—
Other investigative procedure of eye
XCW99 [2001301491]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
0
7
141
1383
Generalized anxiety disorder
F41.1 [45571764]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
—
—
—
—
—
—
follitropin beta; parenteral
G03GA06 [21602604]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
—
—
—
—
—
—
Moderate cervical dysplasia
N87.1 [45534145]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
141
1385
Vaccination
SPAT1325 [2001700426]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
0
7
141
1400
—
Examination of eyes and vision
Z01.0 [45566391]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
0
13
142
1395
—
—
—
0
14
141
1393
—
Acute maxillary sinusitis
J01.0 [45601112]
—
-1.0e+50
—
—
—
—
7.1e-01
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
cases:6.38%
controls:3.24%
—
0
5
142
1403
—
—
—
—
9
45
132
1345
codeine and paracetamol
N02AJ06 [1123647]
6.2e-01
9.3e-01
—
—
—
1.2e+00
6.9e-01
cases:5.63%
controls:3.13%
cases:3.52%
controls:1.42%
—
—
—
—
—
—
cases:5.67%
controls:1.78%
cases:10.64%
controls:5.61%
8
44
134
1364
5
20
137
1388
—
—
—
8
25
133
1382
15
78
126
1312
Calcium [Moles/volume] corrected for albumin in Serum or Plasma
29265-6 [3020059]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
—
—
—
—
—
—
Candidiasis of vulva and vagina
B37.3 [45605230]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
141
1385
Exploration of soft tissue of pelvis, percutaneous
NEA10 [2001307877]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
142
1401
—
—
—
—
—
—
Bicarbonate [Moles/volume] standard in Capillary blood
19231-0 [3004490]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
142
1400
—
—
—
—
—
—
norethisterone and ethinylestradiol
G03AA05 [21602478]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
0
10
142
1398
—
—
—
—
—
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
0
8
141
1399
—
Presence of intraocular lens
Z96.1 [45585885]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
142
1402
—
—
—
—
—
—
fluticasone furoate
R03BA09 [45893496]
—
—
-1.0e+50
—
-1.0e+50
—
8.4e-01
—
—
—
—
cases:0.00%
controls:0.50%
—
—
cases:0.00%
controls:0.36%
—
—
cases:7.80%
controls:3.53%
—
—
0
7
142
1401
—
0
5
142
1403
—
11
49
130
1341
Supervision of other normal pregnancy
Z34.8 [45537628]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
142
1398
—
—
—
—
—
—
beclometasone; inhalant
R03BA01 [21603284]
1.7e+00
1.7e+00
—
—
—
—
—
cases:4.93%
controls:0.92%
cases:3.52%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
7
13
135
1395
5
9
137
1399
—
—
—
—
—
Nonallergic asthma
J45.1 [45557625]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
17
142
1391
—
—
—
—
—
—
simvastatin; oral
C10AA01 [21601856]
—
—
—
—
-1.0e+50
—
-3.0e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
cases:3.55%
controls:4.75%
—
—
—
—
0
10
142
1398
—
5
66
136
1324
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
2.2e-01
—
—
—
—
—
1.7e-01
cases:3.52%
controls:2.84%
—
—
—
—
—
—
—
—
—
—
cases:5.67%
controls:4.82%
5
40
137
1368
—
—
—
—
—
8
67
133
1323
Immunodeficiency with predominantly antibody defects, unspecified
D80.9 [45533002]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
141
1385
Nursing episode
950 [44777714]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
0
7
141
1383
dexamethasone
D07AB19 [21602116]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
0
9
141
1381
orphenadrine (citrate); oral, parenteral
M03BC01 [21604112]
5.8e-01
—
—
—
—
—
2.6e-03
cases:4.23%
controls:2.41%
—
—
—
—
—
—
—
—
—
—
cases:4.26%
controls:4.24%
6
34
136
1374
—
—
—
—
—
6
59
135
1331
frovatriptan; oral
N02CC07 [21604382]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
—
—
—
—
—
—
Diabetic maculopathy and Type 1 diabetes mellitus, With ophthalmic complications
H36.01*E10.3 [2000503946]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
6
141
1384
Exposure to unspecified factor
X59 [45756412]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:1.01%
—
—
—
—
—
—
5
14
136
1376
Lumbar puncture
TAB00 [2001300538]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
142
1399
—
—
—
—
—
—
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
—
—
—
—
—
—
4.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.38%
controls:4.10%
—
—
—
—
—
—
9
57
132
1333
Acute stress reaction
F43.0 [45591139]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
6
141
1384
diclofenac
D11AX18 [21602355]
-1.0e+50
—
—
—
—
-1.0e+50
1.3e+00
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
cases:3.55%
controls:1.01%
0
10
142
1398
—
—
—
—
0
9
141
1398
5
14
136
1376
Natriuretic peptide B [Mass/volume] in Serum or Plasma
30934-4 [3011960]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
—
—
—
—
—
—
encephalitis, tick borne, inactivated, whole virus
J07BA01 [21601331]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
0
5
142
1403
—
—
—
—
0
6
141
1384
Phakoemulsification with implantation of artificial lens in posterior chamber
CJE20 [2001301342]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
142
1399
—
—
—
—
—
—
dexamethasone
S02BA06 [21605168]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
0
9
141
1381
Antenatal screening for malformation
717800004 [36713462]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
0
12
141
1395
—
Ultrasound examination of pregnancy (at 12. week of gestaion or later) including basic examination of fetus
MA2AE [2001306829]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
0
5
142
1403
—
—
—
0
5
141
1402
—
Resection of long saphenous vein
PHD76 [2001309493]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
141
1385
propranolol; oral, parenteral
C07AA05 [21601670]
5.9e-01
1.7e+00
—
—
—
1.5e+00
7.0e-01
cases:3.52%
controls:1.99%
cases:3.52%
controls:0.64%
—
—
—
—
—
—
cases:3.55%
controls:0.85%
cases:4.26%
controls:2.16%
5
28
137
1380
5
9
137
1399
—
—
—
5
12
136
1395
6
30
135
1360
other antifungals for topical use - combinations; ointment
D01AE20 [21601959]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
0
8
142
1400
—
—
—
—
—
alprazolam; oral
N05BA12 [21604577]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
0
7
142
1401
—
—
—
—
—
chlorhexidine
S03AA04 [21605193]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
0
8
142
1400
—
—
—
—
—
Leukocytes [#/volume] in Blood
26464-8 [3010813]
-2.1e-02
-2.7e-01
—
—
—
-5.4e-02
6.9e-02
cases:6.34%
controls:6.46%
cases:4.23%
controls:5.47%
—
—
—
—
—
—
cases:5.67%
controls:5.97%
cases:12.77%
controls:12.01%
9
91
133
1317
6
77
136
1331
—
—
—
8
84
133
1323
18
167
123
1223
Restricted oral and dental health check by dental hygienist or dental assistant
SAB01 [2001310279]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
—
—
—
—
—
—
Assessment of need for psychiatric treatment
IAA01 [2001304011]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
142
1403
—
—
—
—
—
—
Photography of fundus of the eye or interpretation of photograph
SPAT1008 [2001700109]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
141
1385
mercaptopurine
L01BB02 [21601428]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.50%
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
0
7
142
1401
0
5
142
1403
—
—
—
—
—
Case Management Agency
251B00000X [38004193]
-2.3e-01
-4.4e-02
1.8e-01
—
5.1e-01
-1.0e-01
8.8e-02
cases:18.31%
controls:21.95%
cases:14.08%
controls:14.63%
cases:7.75%
controls:6.53%
—
—
cases:8.45%
controls:5.26%
cases:14.89%
controls:16.20%
cases:34.04%
controls:32.09%
26
309
116
1099
20
206
122
1202
11
92
131
1316
—
12
74
130
1334
21
228
120
1179
48
446
93
944
dexamethasone and antiinfectives
S01CA01 [21603652]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
10
141
1380
Impingement syndrome of shoulder
M75.4 [45553266]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
141
1385
Spontaneous abortion, Complete or unspecified, without complication
O03.9 [45563040]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
6
141
1384
insulins and analogues for injection, intermediate-acting - combinations; parenteral
A10AC30 [21600727]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
—
cases:0.00%
controls:1.85%
cases:0.00%
controls:1.63%
cases:0.00%
controls:0.50%
—
—
cases:0.00%
controls:0.50%
cases:0.00%
controls:1.92%
—
—
0
26
142
1382
0
23
142
1385
0
7
142
1401
—
0
7
142
1401
0
27
141
1380
—
glyceryl trinitrate; local oral, oral, sublingual, transdermal
C01DA02 [21600317]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
0
6
141
1401
—
aciclovir; oral, parenteral
J05AB01 [21603131]
—
—
—
—
—
—
4.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:2.30%
—
—
—
—
—
—
5
32
136
1358
valsartan; oral
C09CA03 [21601826]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
142
1401
—
—
—
—
—
—
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.64%
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
0
9
142
1399
0
5
142
1403
—
—
—
0
6
141
1401
—
Demanding placement of orthodontic arch wire
SJD30 [2001310440]
—
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:0.00%
—
—
—
—
—
—
5
0
136
1390
bisoprolol and thiazides
C07BB07 [21601714]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
141
1385
Submucous cleft palate
Q35.71 [2000503339]
1.0e+50
1.0e+50
—
—
—
1.0e+50
1.0e+50
cases:6.34%
controls:0.00%
cases:6.34%
controls:0.00%
—
—
—
—
—
—
cases:4.26%
controls:0.00%
cases:4.96%
controls:0.00%
9
0
133
1408
9
0
133
1408
—
—
—
6
0
135
1407
7
0
134
1390
Abnormal findings in specimens from female genital organs, abnormal cytological findings
R87.6 [45558487]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
0
7
142
1401
—
—
—
—
—
0
11
141
1379
losartan and diuretics
C09DA01 [21601834]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.36%
cases:0.00%
controls:0.50%
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
0
5
142
1403
0
7
142
1401
—
—
—
0
7
141
1400
—
Pulmonary Disease
29 [38004472]
—
—
—
—
—
—
6.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.26%
controls:2.37%
—
—
—
—
—
—
6
33
135
1357
Contraception female other
W14 [2002001214]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
141
1385
acetylsalicylic acid; oral, parenteral, rectal
N02BA01 [21604305]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
0
7
141
1383
Upper respiratory infection acute
R74 [2002000942]
—
—
—
—
—
-1.0e+50
5.1e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
cases:4.26%
controls:2.59%
—
—
—
—
—
0
10
141
1397
6
36
135
1354
Anxiety disorder, unspecified
F41.9 [45542849]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:0.94%
—
—
—
—
—
—
5
13
136
1377
Medical Oncology
90 [38004507]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
142
1400
—
—
—
—
—
—
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
0
6
141
1401
—
Chronic sinusitis, unspecified
J32.9 [45596278]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
141
1385
Day surgery
ZXD20 [2001311388]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
142
1402
—
—
—
—
—
—
Local application of medicine to mouth
SXA20 [2001310579]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
6
141
1384
amitriptyline and psycholeptics
N06CA01 [21604789]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.35%
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
0
19
142
1389
0
9
142
1399
—
—
—
—
—
Other stressful life events affecting family and household
Z63.7 [45537662]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.57%
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
0
8
142
1400
0
5
142
1403
—
—
—
—
—
The fear of childbirth
O99.80 [2000503219]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
0
5
142
1403
—
—
—
—
—
0
6
141
1384
Lumbar and other intervertebral disc disorders with radiculopathy
M51.1 [45562747]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
0
5
141
1402
—
dexchlorpheniramine, combinations
R06AB52 [21603467]
1.1e+00
—
—
—
—
-1.0e+50
—
cases:6.34%
controls:2.27%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
9
32
133
1376
—
—
—
—
0
5
141
1402
—
Back syndrome without radiat pain
L84 [2002000703]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
141
1385
atenolol; oral, parenteral
C07AB03 [21601685]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
142
1402
—
—
—
—
—
—
fusidic acid; ointment
D06AX01 [21602062]
2.7e-01
-1.0e+50
—
—
—
-1.0e+50
9.7e-01
cases:3.52%
controls:2.70%
cases:0.00%
controls:0.64%
—
—
—
—
—
—
cases:0.00%
controls:0.57%
cases:4.26%
controls:1.65%
5
38
137
1370
0
9
142
1399
—
—
—
0
8
141
1399
6
23
135
1367
One-surface restoration
SFA10 [2001310358]
5.2e-01
—
-1.0e+50
—
—
—
6.5e-01
cases:4.23%
controls:2.56%
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
cases:11.35%
controls:6.26%
6
36
136
1372
—
0
6
142
1402
—
—
—
16
87
125
1303
levocetirizine; oral
R06AE09 [21603498]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
0
8
142
1400
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
27
163
1.77
1.84
1.3
1.7
—
—
—
0
0
18
95
1.99
1.83
6.8
17.3
0.89
0.86
mmol/l
0.01
13
84
18
95
1.99
1.83
7.2
17.3
7.48
7.43
ph
—
5
51
23
137
1.78
1.65
7.5
10.8
105.74
104.67
mmol/l
0.89
23
137
21
124
1.78
1.55
5.2
10.3
7.36
7.37
ph
0.24
13
73
17
95
1.87
1.49
4.7
10.7
23.51
23.99
mmol/l
0.28
17
95
135
1476
0.67
1.47
4.8
5.2
1.82
1.73
mu/l
0.46
129
1410
28
183
1.63
1.45
1.9
1.7
—
—
—
0
0
125
1373
0.72
1.24
3.7
3.6
5.58
5.56
mmol/l
0.06
115
1293
134
1453
0.71
1.20
4.0
4.1
2.98
2.77
mmol/l
2.20
126
1400
8
39
2.10
1.17
1.3
16.2
—
—
—
0
0
11
58
1.95
1.14
10.3
16.2
96.15
93.69
%
1.15
11
58
40
519
0.71
1.13
1.9
2.0
—
—
—
0
0
48
602
0.73
1.10
1.8
1.8
1.37
1.28
mmol/l
0.39
43
539
11
59
1.92
1.10
10.2
15.9
1.01
1.33
%
0.72
11
59
134
1445
0.73
1.05
3.6
3.8
1.43
1.46
mmol/l
0.40
127
1393
28
200
1.47
1.01
1.6
1.5
—
—
—
0
0
0
30
0.00
0.98
0.0
1.0
—
—
—
0
0
7
36
1.98
0.98
5.9
5.6
36.97
36.97
°c
—
7
36
158
1490
1.44
0.91
11.2
11.7
139.54
139.60
mmol/l
0.12
152
1454
158
1491
1.44
0.90
11.3
11.8
3.92
3.91
mmol/l
0.34
150
1450
10
56
1.83
0.89
10.4
16.6
0.62
0.61
%
—
10
56
117
1273
0.78
0.86
4.2
4.4
36.84
36.66
mmol/mol
0.08
110
1231
10
57
1.80
0.85
10.9
16.0
23.99
24.54
mmol/l
—
10
57
136
1450
0.76
0.84
3.7
3.9
4.79
4.63
mmol/l
1.31
129
1403
86
754
1.27
0.82
2.6
2.9
—
—
estimate
—
0
0
13
82
1.63
0.80
3.3
6.0
—
—
—
0
0
21
285
0.70
0.76
1.2
1.4
25.50
10.19
u/ml
—
10
112
119
1090
1.26
0.76
4.3
4.3
—
—
—
0
0
40
321
1.31
0.75
1.6
1.6
—
—
—
0
0
65
559
1.25
0.72
3.5
3.8
25.98
99.30
e6/l
0.71
44
353
7
43
1.65
0.67
1.1
1.1
—
—
—
0
0
59
505
1.25
0.67
2.1
2.2
—
—
—
0
0
53
449
1.25
0.66
14.2
8.3
1.17
1.08
inr
0.60
37
373
24
309
0.74
0.64
1.2
1.3
36.23
15.86
iu/ml
—
7
86
95
860
1.22
0.63
3.4
3.5
0.00
0.00
estimate
-0.00
15
165
13
88
1.51
0.62
1.2
1.2
—
29.44
—
0
5
5
30
1.68
0.62
4.0
15.0
65.56
65.18
%
—
5
30
16
116
1.42
0.56
10.5
13.6
—
—
—
0
0
127
1344
0.82
0.56
3.1
3.3
1.29
1.17
mmol/l
1.07
117
1284
12
82
1.50
0.56
1.2
1.1
1.48
1.55
g/l
0.48
12
82
12
83
1.48
0.53
1.2
1.1
0.93
0.86
g/l
0.41
12
83
53
460
1.21
0.53
2.7
3.1
16.36
38.86
e6/l
1.10
41
330
24
189
1.31
0.53
2.0
2.3
—
—
—
0
0
15
109
1.41
0.53
8.5
13.8
24.97
24.89
mmol/l
0.04
15
109
93
852
1.19
0.51
3.4
3.4
0.00
0.00
estimate
-0.00
15
169
92
843
1.18
0.51
3.4
3.4
0.00
0.00
estimate
-0.00
15
174
77
696
1.18
0.49
3.1
3.2
6.31
6.29
ph
0.03
36
384
89
815
1.18
0.49
4.8
6.0
6.19
6.22
mmol/l
0.04
79
727
29
350
0.80
0.49
6.7
3.1
7.40
7.39
ph
0.30
19
248
36
303
1.23
0.48
2.7
3.7
—
—
—
0
0
16
120
1.37
0.48
3.3
2.1
12.91
12.56
nmol/l
0.05
16
111
5
84
0.58
0.46
1.0
1.8
—
—
—
0
0
12
86
1.42
0.46
1.2
1.4
—
—
—
0
0
44
381
1.20
0.45
3.6
2.5
38.48
34.38
ng/l
0.07
22
164
18
140
1.32
0.44
1.7
1.3
—
—
—
0
0
8
57
1.42
0.42
5.5
10.1
0.59
0.59
%
—
8
57
8
57
1.42
0.42
5.5
10.1
0.96
1.44
%
—
8
57
55
489
1.18
0.42
9.7
7.7
—
—
—
0
0
0
15
0.00
0.41
0.0
1.4
—
91.83
—
0
15
21
169
1.27
0.41
1.3
1.5
—
—
—
0
0
43
489
0.84
0.41
1.3
1.5
1.79
2.20
g/l
1.62
29
311
0
17
0.00
0.41
0.0
2.8
—
41.35
—
0
17
45
509
0.85
0.40
2.7
2.6
0.00
0.00
estimate
-0.00
14
146
8
114
0.69
0.38
1.3
1.2
—
—
—
0
0
58
640
0.86
0.38
1.9
1.8
—
—
—
0
0
111
1048
1.15
0.38
3.9
4.3
—
331.82
—
0
11
44
389
1.17
0.36
2.8
3.1
—
—
estimate
—
0
0
11
82
1.36
0.35
1.5
4.0
22.64
20.47
s
0.86
11
73
13
100
1.32
0.34
1.1
1.1
—
—
—
0
0
68
734
0.88
0.31
12.0
9.7
0.00
0.00
e9/l
0.99
54
591
87
925
0.89
0.31
10.1
9.7
4.22
3.94
e9/l
0.46
78
812
12
152
0.77
0.31
2.3
1.9
—
—
—
0
0
165
1614
1.23
0.30
9.9
9.4
26.65
26.00
u/l
0.15
158
1584
29
330
0.86
0.28
1.9
1.5
17.46
20.32
nmol/l
0.65
24
298
11
139
0.78
0.28
3.9
3.1
1.61
1.41
ug/l
0.20
11
128
54
584
0.89
0.25
1.8
1.8
—
—
—
0
0
26
228
1.16
0.24
3.0
3.3
4.79
2.28
e6/l
—
10
105
14
115
1.24
0.24
1.1
1.2
—
151.67
—
0
6
43
393
1.12
0.23
2.8
3.1
0.37
0.25
e6/l
0.49
32
272
5
39
1.29
0.23
1.0
1.2
—
—
—
0
0
5
40
1.26
0.22
1.8
1.7
10.00
7.20
mmol/l
—
5
40
18
209
0.85
0.22
1.4
2.3
2623.50
5501.27
u/l
—
8
92
0
11
0.00
0.21
0.0
2.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
2.9
—
—
—
0
0
37
405
0.89
0.21
4.7
4.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.8
—
0.91
—
0
7
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
1.73
—
0
12
0
13
0.00
0.21
0.0
1.8
—
64.08
—
0
13
0
13
0.00
0.21
0.0
2.4
—
0.65
—
0
13
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
0.32
—
0
9
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
124
1276
0.91
0.19
3.9
4.5
14.11
14.45
pmol/l
0.89
116
1196
6
51
1.18
0.19
1.3
1.1
—
—
—
0
0
55
515
1.10
0.19
1.6
1.8
90.85
97.75
pmol/l
0.84
30
284
11
132
0.82
0.19
1.8
1.7
—
—
—
0
0
6
53
1.14
0.19
1.2
1.3
—
64.00
—
0
5
15
174
0.85
0.18
1.1
1.5
—
—
—
0
0
10
121
0.82
0.18
1.1
1.5
—
—
—
0
0
95
916
1.08
0.16
2.9
3.3
71.38
67.74
ug/l
0.18
90
884
18
203
0.87
0.16
2.6
2.6
13.57
14.20
umol/l
0.14
18
189
61
641
0.93
0.15
2.8
2.4
—
—
—
0
0
11
129
0.84
0.15
1.8
1.6
—
—
—
0
0
13
113
1.16
0.13
1.1
1.6
—
—
—
0
0
9
108
0.82
0.13
3.1
1.9
2.21
1.26
g/l
—
9
102
15
133
1.14
0.12
1.6
1.4
174.43
300.84
miu/ml
—
10
76
51
535
0.94
0.12
1.2
1.5
0.57
3.67
u/ml
1.76
12
129
43
407
1.07
0.12
3.0
3.5
8.73
8.69
mmol/l
0.01
37
372
12
136
0.87
0.11
3.0
2.9
—
—
—
0
0
27
290
0.92
0.11
3.3
3.6
62.23
81.97
mg/l
0.23
20
200
60
576
1.06
0.11
1.7
1.8
—
—
—
0
0
13
115
1.14
0.11
3.4
4.7
1.67
1.63
%
0.03
13
108
56
538
1.06
0.10
8.6
8.6
1.21
1.22
mmol/l
0.22
51
503
6
54
1.11
0.09
1.0
1.4
—
—
—
0
0
43
449
0.94
0.08
2.6
2.4
—
—
—
0
0
5
64
0.78
0.08
1.4
1.6
—
—
—
0
0
31
327
0.94
0.08
4.4
2.6
—
—
—
0
0
83
850
0.96
0.08
8.7
7.4
0.20
0.18
e9/l
0.43
76
766
17
157
1.09
0.07
1.1
1.2
—
—
—
0
0
9
100
0.89
0.06
1.1
1.1
—
—
—
0
0
159
1577
1.06
0.06
11.9
11.7
23.17
21.01
mg/l
0.32
135
1249
12
131
0.91
0.06
1.4
1.6
350.42
331.35
mu/l
0.10
12
121
69
705
0.97
0.05
2.0
2.3
—
—
—
0
0
20
189
1.07
0.05
1.1
1.5
—
—
—
0
0
28
292
0.95
0.05
3.9
4.2
7.91
12.36
mg/mmol
0.35
18
194
80
814
0.97
0.04
8.6
6.9
0.57
0.53
e9/l
0.84
74
718
41
398
1.04
0.04
1.7
1.7
—
—
—
0
0
43
442
0.96
0.04
3.3
3.3
0.00
0.01
estimate
0.50
16
171
20
190
1.06
0.04
1.1
1.5
—
—
—
0
0
17
161
1.06
0.03
2.4
2.8
20.62
23.34
%
0.51
17
149
20
209
0.95
0.03
1.1
1.2
—
—
—
0
0
20
192
1.05
0.02
1.1
1.5
—
—
—
0
0
20
192
1.05
0.02
1.1
1.5
—
—
—
0
0
22
228
0.96
0.02
2.6
3.1
806.25
253.98
ng/l
0.30
12
125
83
839
0.98
0.02
8.4
6.9
2.10
1.96
e9/l
0.79
77
761
10
93
1.08
0.02
1.2
1.2
—
—
—
0
0
39
398
0.97
0.02
3.0
3.3
1.02
1.02
kg/l
0.06
19
251
66
652
1.02
0.01
3.0
3.1
0.00
0.01
estimate
0.50
15
152
19
183
1.04
0.01
1.1
1.2
—
—
—
0
0
12
116
1.04
0.00
2.4
3.6
4.62
4.76
pmol/l
0.21
12
105
164
1644
0.98
0.00
10.0
9.9
—
—
—
0
0
35
353
0.99
0.00
2.1
2.3
0.92
1.21
mg/l
0.35
24
259
104
1043
0.99
0.00
7.6
6.8
80.17
77.45
u/l
0.22
98
982
48
478
1.01
0.00
5.3
5.7
—
—
—
0
0
12
125
0.96
0.00
1.9
2.0
6.17
6.27
ph
—
6
79
81
814
0.99
0.00
8.5
6.9
0.04
0.04
e9/l
0.10
74
714
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
6.8
—
120.62
—
0
9
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
1.97
—
0
6
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.3
—
16.43
—
0
6
0
7
0.00
-0.00
0.0
10.6
—
7.74
—
0
7
0
7
0.00
-0.00
0.0
1.3
—
154.71
—
0
7
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
10.20
—
0
6
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.7
—
31.78
—
0
9
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
123.64
—
0
5
0
5
0.00
-0.00
0.0
2.4
—
3.20
—
0
5
0
6
0.00
-0.00
0.0
3.0
—
—
—
0
0
9
89
1.01
-0.00
1.0
1.1
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint Q17_CLEFT_HARD_PALATE_NOS and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have Q17_CLEFT_HARD_PALATE_NOS.

N-year risk Females Males
1 No data No data
5 No data No data
10 No data No data
15 No data No data
20 No data No data

Relationships between endpoints

↥

Index endpoint: Q17_CLEFT_HARD_PALATE_NOS – Cleft hard palate NOS

GWS hits: 2

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data